Friday, July 31, 2026

Trump’s 25% AI Chip Tariff Forces Seoul to Stay Put: What It Signals for Tech Trade

South Korea's Trade Bureau head Yeo Han Koo delays return to assess impact of U.S. tariffs on AI semiconductors and industry cooperation.

ChatGPT Can Now Read Your GitHub Code — Here’s What That Means

OpenAI enhances ChatGPT with a GitHub connector for deep research, aiding developers in code analysis and documentation tasks.

Trump Open to Unconditional Talks with Kim: What This Means for U.S.-North Korea Relations in 2026

President Trump is open to dialogue with Kim Jong Un if the U.S. respects North Korea's nuclear status, suggesting potential negotiations.

Tag: GLP-1

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

‘Dream Weight-Loss Drug’ Wegovy May Also Protect Brain Health by Reducing Risk of Adult-Onset Seizures

Semaglutide may reduce adult-onset seizure risk by 56%, suggesting a link between metabolic treatment and brain health.

AstraZeneca’s Elecoglipron: Can This New Weight Loss Pill Compete with GLP-1 Giants?

AstraZeneca's new weight-loss pill, elecoglipron, shows promising results in trials, competing with existing obesity treatments.

Wegovy Breaks Records: 3 Million Prescriptions in Just 5 Months – What You Need to Know

Wegovy surpasses 3 million prescriptions in 5 months, marking a significant milestone in the U.S. obesity treatment market.

Wegovy, Mounjaro Boom Creates New Winners as Ursa, InBody Ride GLP-1 Ripple Effects

GLP-1 obesity drugs are boosting gallstone prevention therapies and body composition monitoring, creating new market opportunities.

Samsung Launches GLP-1 Muscle Loss Study With Galaxy Watch8 and Harvard-Linked Hospital

Samsung is researching muscle loss management for GLP-1 drug users, led by the Galaxy Watch 8.

Celltrion Moves CT-G32 Into Final Preclinical Stage as Global Obesity Trial Preparation Accelerates

Celltrion advances CT-G32, a next-gen obesity treatment, targeting multiple pathways to enhance weight loss while preserving muscle mass.

MetaVia to Present DA-1726 Phase 1 Obesity Trial Data at EASL Congress 2026

Dong-A ST's Meta via will present DA-1726, a dual-action obesity treatment, at the EASL Congress 2026, showcasing promising clinical trial results.

Novo Nordisk’s Oral Wegovy Just Put Up a Number That Could Change the Obesity Drug Race

Novo Nordisk's oral obesity treatment, Wegovy, saw $400M in Q1 2026 sales, exceeding estimates and indicating strong market demand.

Unlocking Weight Loss: How GB102 Probiotics Enhance GLP-1 Obesity Drugs

GI Longevity's GB102 probiotic enhances weight loss with GLP-1 medications, reducing rebound gain and improving blood sugar control.

Metabia Begins Dosing First Patient in Phase 1 Part 3 Trial of Obesity Drug DA-1726

Metabia begins Phase 1 trial for DA-1726, a dual-action obesity treatment, aiming for safety and efficacy in weight loss by 2026.

Eli Lilly’s New Weight Loss Pill Foundayo: A Game Changer in the GLP-1 Market?

The FDA has approved Eli Lilly's oral obesity drug Foundayo, enhancing competition in the weight loss market with flexible dosing.

DA-1726: The New Dual-Action Obesity Treatment Set to Transform Weight Loss in 2026

MetaVia's DA-1726 obesity treatment trial approved by U.S. IRB, focusing on dual-action GLP-1 and Glucagon receptors for weight loss.

GLP-1 Weight Loss Injections: Are They Causing Gallstone Surge in Asia?

GLP-1 obesity treatments are linked to increased gallstone risk, especially during rapid weight loss, with cases doubling in South Korea.

Novo Nordisk Slashes GLP-1 Drug Prices by Up to 50%: What This Means for Obesity Treatments in 2027

Novo Nordisk will cut prices of GLP-1 treatments in the U.S. by up to 50% from January 2027, amid rising competition and market pressures.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.